|
Acetazolamide
|
Related to an increase of cerebral perfusion evaluated by perfusion MRI [156], transcranial Doppler sonography [157] and Tc-99 m extracellular domain brain perfusion SPECT [158, 159]
|
|
Atorvastatin
|
No effects on cerebral blood flow [160], tested with transcranial Doppler
|
|
L-arginine
|
Induced-vasoreactivity [161], tested with transcranial Doppler
|
|
Sapropterin (200–400 mg bid in 24 months)
|
Final results for the primary end-point (mean difference in reactive hyperemia index) were not significant for any improvement of peripheral vasoreactivity [162]
|
|
Novel molecular therapeutic target (as stem cell factor and granulocyte-colony stimulating factor)
|
Ongoing [163]
|
